CytoGenix Inc has filed a patent application for a novel business structure for providing the Oligonucleotide-Mediated Intervention Therapies currently under development by the company.
CytoGenix is a Houston based biotechnology research and development company with proprietary technology for the intracellular expression of sequence specific single strands of DNA for purposes of intervening in the production of disease causing proteins.
CytoGenix President and CEO, Malcolm Skolnick explains, "The increasing understanding of genetics, molecular biology and the genomic basis of disease promises important new approaches to interrupting the disease process and achieving preventative and curative techniques which will markedly extend medicine's ability to protect and preserve an individual's health and welfare. To accomplish this, it will be necessary to construct interfaces between the scientific knowledge about individual diseases, the genomic bases of the disease process, the interventive genomic technology which can disrupt or prevent the disease process, the relationship of an individual's genomic information and the interventive technology, the technology needed to generate the appropriate genomic therapeutic or diagnostic modality required, and the essential human participation to utilize the appropriate scientific and technological information, compound the determined medication and provide it to the patient."
The present invention relates to a system and method for managing and supporting the construction and delivery of genomically derived substances for pharmaceutical applications. These substances include sequences of nucleotides and nucleic acid substances, which may be combined with other chemicals using pharmaceutical compounding in response to physicians' prescriptions for delivery to an individual.
The system further involves identifying an individual patient's genomic characteristics used to optimize selection of the pharmacogenomic substances to be included in a given prescription, selecting parameters from appropriate data bases required to produce a given pharmacogenomic substance which can provide therapeutic or diagnostic benefit to an individual patient together with means for effectively delivering it and facilitating uptake in affected tissues and/or cells, generating the required pharmacogenomic substance together with effective application or delivery means in appropriate amounts, enabling a pharmacist to respond to a physician prescription and compound the prescription and recording the details of the transaction.
An additional integral part of the system is the ability to deliver, assess, and document the patient's understanding of an informed consent process critical to innovative healthcare.